Antengene Corporation Limited will present new data from two late-stage clinical trials evaluating selinexor at the 2024 American Society of Hematology (ASH) Annual Meeting, to be held December 7-10 in San Diego, CA. The presentations will feature results from a Phase III study of selinexor in relapsed/refractory multiple myeloma (RRMM) and a Phase I/II study in relapsed/refractory extranodal NK/T-cell lymphoma (R/R ENKTL). These data presentations highlight the potential of selinexor-based regimens to address unmet needs in these hematologic malignancies.
Selinexor, Bortezomib, and Dexamethasone in RRMM
The first presentation (Poster #4748) will detail the primary analysis of the Phase III BENCH study, which evaluated weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice-weekly bortezomib and dexamethasone (Vd) in Chinese patients with RRMM. This study addresses the need for more effective and tolerable regimens in RRMM patients who have failed prior lines of therapy. The presentation will include efficacy and safety data, providing insights into the potential of the SVd combination as a treatment option for this patient population. Dr. Jin Lu (Peking University People's Hospital) is the first author, and Dr. Jian Hou (Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine) is the corresponding author.
Selinexor and Tislelizumab in R/R ENKTL
The second presentation (Poster #4448) will feature preliminary results from Arm C of the TOUCH study, a multicenter, single-arm, Phase I/II trial investigating selinexor in combination with tislelizumab in patients with R/R ENKTL. ENKTL is an aggressive lymphoma subtype with limited treatment options, particularly in the relapsed/refractory setting. This study explores the potential synergistic activity of selinexor and tislelizumab, an anti-PD-1 antibody, to improve outcomes in these patients. Dr. Rong Tao (Fudan University Shanghai Cancer Center) is the first author, and Dr. Huiqiang Huang (Sun Yat-Sen University Cancer Center) is the corresponding author.
About Selinexor
Selinexor (XPOVIO®) is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. It functions by blocking the nuclear export protein XPO1, leading to the accumulation and activation of tumor suppressor proteins within the nucleus, while simultaneously reducing the levels of oncogenic proteins in the cytoplasm. This dual mechanism of action allows selinexor to exert antitumor effects through multiple pathways, including inducing tumor suppressor protein activity, reducing oncogenic protein levels, and restoring hormone sensitivity. Antengene is currently evaluating selinexor in multiple clinical trials in mainland China for the treatment of relapsed/refractory hematologic malignancies and solid tumors.
